Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma

Investigational New Drugs - Tập 2 - Trang 331-333 - 1984
Frederick B. Stehman1, John A. Blessing2, Howard D. Homesley3, John L. Currie4, Edgardo L. Yordan5
1Indiana University Medical Center, Indianapolis, USA
2Roswell Park Memorial Institute, Buffalo, USA
3Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, USA
4University of North Carolina School of Medicine, Chapel Hill, USA
5Rush-Presbyterian St. Luke's Medical Center, Chicago, USA

Tóm tắt

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

Tài liệu tham khảo

Stehman FB, Blom J, Blessing JA, Ehrlich CE, and Mangan C: Phase II trial of galactitol 1,2:5,6 dianhydro (NSC #132313) in the treatment of advanced gynecologic malignancies (a Gynecologic Oncology Group study). Gynecol Onc 15:381–390, 1983 Stehman FB, Blessing JA, Delgado G, and Louka M: Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma (a Gynecologic Oncology Group study). Cancer Treat Rep 67:737–738, 1983
Thông tin
Thông tin xuất bản

Investigational New Drugs

Tập 2

331-333

Thông tin tác giả